Substituted pteridinones for the treatment of cancer

US9351974B2 · kind B2 · utility

Assignee

• OSI Pharmaceuticals, LLC · US

Inventors

• Meizhong Jin · Dix Hills, US
• Mridula Kadalbajoo · Farmingdale, US
• An-Hu Li · New York, US
• Mark J. Mulvihill · Melville, US
• Kam W. Siu · Milford, US
• Arno G. Steinig · East Northport, US
• Jing Wang · Acton, US

Key dates

• Filing date: Nov 12, 2012
• Grant date: May 31, 2016
• Expiry date: Nov 12, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/5025
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I, as shown below and defined herein:pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at least in part by RSK. This Abstract is not limiting of the invention.